Maxim bullish on Abeona, sees 89% upside on prospects of lead gene therapy candidate EB-101; shares up 2% – Seeking Alpha
Thorold News |
Maxim bullish on Abeona, sees 89% upside on prospects of lead gene therapy candidate EB-101; shares up 2%
Seeking Alpha Maxim Group ups its fair value target for Abeona Therapeutics (ABEO +2.2%) to $17 (89% upside) from $14 citing positive prospects for its lead gene therapy candidate, Orphan Drug-tagged EB-101, for the treatment of recessive dystrophic epidermolysis … Maxim Group Just Issued “Buy” Rating on Abeona Therapeutics Inc (ABEO) Analysts are on the Bearish side about Abeona Therapeutics Inc (NASDAQ:ABEO) this week. |
